The IPO and listing projects of Jiangxi Fushine Pharmaceutical Co., Ltd, for which Grandway has provided legal service, have been approved by CSRC

On June 12th, 2015, he IPO and listing projects of Jiangxi Fushine Pharmaceutical Co., Ltd, for which Grandway has provided legal service, were approved by the 56th committee of CSRC.
Fushine Pharmaceutical was founded in 2002, locating at a prestigious historic city and famous Millennium Porcelain Capital in China — Jingdezhen. Armed with advanced production equipments and manufacturing technologies, Fushine is specialized in the R & D, manufacture and sales of APIs and pharmaceutical intermediates. the company is a “National High-Technology Enterprise”, “Excellent
Enterprise in Jiangxi Province”, Excellent Non-state-owned Enterprise in Jiangxi Province, Innovation-based Pilot Enterprise in Jiangxi Province”, and has set the  “Provincial enterprise technology center”. The company has three wholly-owned subsidiaries including Jiangxi Xiangtai Pharmaceutical Co., Ltd etc.
The company owns the key technology and currently is the biggest API manufacturer of β—lactamase inhibitors, and also the leading supplier of Carbapenem intermediates. Based on the advantages of production technology, quality management, EHS management and customer services, as well as the comprehensive and integrated risk management and control, our company enjoys a great reputation and cooperation with domestic and international customers, and our products are spread more than ten countries globally and regions in the globe.